
    
      This is an open-label (identity of assigned study drug will be known) early access protocol
      (EAP). Approximately 60 participants will be enrolled in this study. Participants will
      receive abiraterone acetate 1000 mg daily plus prednisone or prednisolone 5 mg daily.
      Treatment in 28-day cycles will continue until progression of clinical disease. Study drug
      will be provided until the company obtains market authorization and reimbursement in the
      participant countries for this indication.
    
  